SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2177829

Cover Image

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2177829

Pet Stem Cell Therapy Market Forecasts to 2034 - Global Analysis By Cell Therapy Type, Clinical Indication, Animal Type, Treatment Setting, Cell Source, Administration Method, and By Geography

PUBLISHED:
PAGES: 300+ Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4150
PDF (2-5 User License)
USD 5250
PDF & Excel (Site License)
USD 6350
PDF & Excel (Global Site License)
USD 7500

Add to Cart

According to Stratistics MRC, the Global Pet Stem Cell Therapy Market is accounted for $0.1 billion in 2026 and is expected to reach $0.2 billion by 2034 growing at a CAGR of 9.1% during the forecast period. The market covers veterinary regenerative treatments using processed cells to address selected companion-animal conditions, including autologous and allogeneic cell products and tissue collection. It is used to provide investigational or jurisdiction-dependent options for orthopedic and inflammatory disorders. Growth reflects clinical research and specialist veterinary adoption and development of regulatory pathways. Market expansion is likely to vary with purchasing power, product performance, regulatory requirements and channel reach.

Market Dynamics:

Driver:

Interest in regenerative approaches for difficult musculoskeletal conditions

Growing interest in regenerative medicine for osteoarthritis, tendon and ligament injuries, and inflammatory conditions is supporting pet stem cell therapy. Owners seek alternatives or adjuncts to long-term medication and surgery. Advances in adipose-derived and allogeneic cell processing, plus specialist veterinary adoption, are expanding clinical options. Referral hospitals and regenerative clinics are building capability. Research into off-the-shelf products and standardized protocols is improving feasibility, while higher pet spending and owner demand for advanced care support premium pricing.

Restraint:

Limited approvals and uneven evidence of safety or effectiveness

Adoption is constrained by limited regulatory approvals, jurisdiction-specific rules and uneven evidence of safety and effectiveness. Many treatments remain investigational or conditionally approved. Variability in cell sourcing, processing and dosing complicates outcome comparison. High costs and limited insurance coverage deter owners. Specialist capacity is concentrated in urban referral centers. Veterinarians may hesitate without robust clinical data. Standardized manufacturing, controlled trials and clear regulatory pathways are essential to build confidence and broaden adoption.

Opportunity:

Controlled clinical research and standardized manufacturing

Opportunity lies in controlled clinical trials, standardized manufacturing and validated outcome measures that strengthen veterinary confidence. Off-the-shelf allogeneic products can improve scalability and reduce cost. Partnerships with referral hospitals, universities and distributors can expand access. Condition-specific protocols for osteoarthritis and tendon injury improve targeting. Insurance collaboration and owner education can support affordability. Cold-chain logistics and quality assurance systems create barriers to entry and differentiation for credible manufacturers.

Threat:

Regulatory enforcement and variability in product quality

The market faces risks from regulatory enforcement, inconsistent product quality and unproven claims that can harm pets and reputations. Variability in cell viability and processing standards undermines outcomes. Negative clinical events or unethical marketing can trigger scrutiny. Competition from established medications, physical rehabilitation and surgery limits adoption. High costs and limited reimbursement constrain demand. Companies need rigorous quality control, transparent evidence and compliant promotion to sustain credibility and market access.

Covid-19 Impact:

The COVID-19 pandemic disrupted veterinary appointments, specialist retail, travel and pet-care supply chains, while shifting more purchasing and advice-seeking online. Some owners postponed non-urgent services, but increased time at home and heightened attention to animal wellbeing supported demand for home-use products and digital support. Providers responded with e-commerce, teleconsultation and flexible scheduling. As restrictions eased, in-person services recovered, but demand for convenience and clear product information remained. The effect varied by market, depending on clinical need, discretionary spending and reliance on in-person experiences where available.

The Adipose-Derived Mesenchymal Cells segment is expected to be the largest during the forecast period

The Adipose-Derived Mesenchymal Cells segment is expected to account for a leading share of the pet stem cell therapy market during the forecast period. Its position reflects the relevance of this group to the addressable companion-animal population and the breadth of use across the market's principal cell therapy type applications. Established product availability, owner familiarity and professional recommendations support demand, while a wide range of care needs encourages repeat purchasing or service use. Market participants are expected to prioritize this segment through targeted product development, broader distribution and clearer use guidance.

The Other Degenerative Disorders segment is expected to have the highest CAGR during the forecast period

The Other Degenerative Disorders segment is expected to have the highest CAGR during the forecast period as providers expand targeted solutions and improve access through veterinary, specialist retail and digital channels. Demand is supported by growing awareness of the relevant need, improved product formulation or service delivery, and increased owner willingness to invest in tailored companion-animal care. As evidence, convenience and availability improve, this segment may attract new entrants and encourage established providers to broaden their portfolios.

Region with largest share:

North America is expected to account for a leading share of the pet stem cell therapy market, supported by high companion-animal ownership, comparatively developed veterinary infrastructure, established pet specialty retail and relatively high per-pet expenditure. The United States represents a major demand center because owners have access to veterinary clinics, online pet-care platforms and a broad selection of specialized products and services. Canada contributes through a mature pet-care ecosystem and established companion-animal health providers. Market adoption is also supported by insurance availability, consumer awareness and product innovation, although adoption differs by income, geography and veterinary access.

Region with highest CAGR:

Asia Pacific is expected to exhibit strong growth in the pet stem cell therapy market as pet ownership, urban household formation, veterinary service availability and organized pet retail expand across major markets. China, Japan, South Korea, India and Australia offer different adoption pathways, reflecting differences in purchasing power, veterinary infrastructure, product regulation and the role of digital commerce. Growing awareness of preventive care and rising demand for premium companion-animal products are likely to support market development. Expansion will depend on localized products, professional education and compliance with national animal-health and consumer-protection requirements.

Key players in the market

Some of the key players in the Global Pet Stem Cell Therapy Market include VetStem, Inc., Gallant, Magellan Stem Cells, Animal Cell Therapies, Medrego, Ardent Animal Health, VetBiologics, VetCell Therapeutics, PetVivo Holdings, Inc., Regeneus Ltd., Cell Therapy Sciences, MWI Animal Health, Cencora, Inc., Kintara Therapeutics, Boehringer Ingelheim Animal Health, Vetherapy, Enso Discoveries.

Key Developments:

In May 2026, Gallant reported positive pilot data for a canine osteoarthritis cell-therapy program and FDA eligibility for an expanded conditional-approval pathway, supporting development of off-the-shelf veterinary regenerative medicine.

In April 2026, Gallant announced positive pilot data for an intravenous cell therapy in cats with naturally occurring osteoarthritis and reported FDA eligibility for an expanded conditional-approval pathway.

In February 2026, Gallant announced a fulfillment agreement with MWI Animal Health to establish an ultra-low-temperature cold chain for veterinary stem-cell therapy distribution, subject to regulatory progress.

Cell Therapy Types Covered:

  • Adipose-Derived Mesenchymal Cells
  • Umbilical and Placental-Derived Cells
  • Allogeneic Off-the-Shelf Cells
  • Autologous Cell Preparations

Clinical Indications Covered:

  • Osteoarthritis
  • Tendon and Ligament Injuries
  • Oral and Inflammatory Conditions
  • Other Degenerative Disorders

Animal Types Covered:

  • Dogs
  • Cats
  • Equine Companion Animals

Treatment Settings Covered:

  • Specialty Veterinary Hospitals
  • Referral Practices
  • Regenerative Medicine Clinics

Cell Sources Covered:

  • Autologous Adipose Tissue
  • Allogeneic Donor Tissue
  • Umbilical and Perinatal Tissue
  • Other Mesenchymal Cell Sources

Administration Methods Covered:

  • Intra-Articular Injection
  • Intravenous Infusion
  • Local Tissue Injection
  • Other Targeted Administration

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for regional and country-level segments
  • Strategic recommendations for new entrants
  • Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
  • Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
  • Strategic recommendations for key business segments based on market estimations
  • Competitive landscape mapping and assessment of key industry trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:

All customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Product Code: SMRC41158

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pet Stem Cell Therapy Market, By Cell Therapy Type

  • 5.1 Adipose-Derived Mesenchymal Cells
  • 5.2 Umbilical and Placental-Derived Cells
  • 5.3 Allogeneic Off-the-Shelf Cells
  • 5.4 Autologous Cell Preparations

6 Global Pet Stem Cell Therapy Market, By Clinical Indication

  • 6.1 Osteoarthritis
  • 6.2 Tendon and Ligament Injuries
  • 6.3 Oral and Inflammatory Conditions
  • 6.4 Other Degenerative Disorders

7 Global Pet Stem Cell Therapy Market, By Animal Type

  • 7.1 Dogs
  • 7.2 Cats
  • 7.3 Equine Companion Animals

8 Global Pet Stem Cell Therapy Market, By Treatment Setting

  • 8.1 Specialty Veterinary Hospitals
  • 8.2 Referral Practices
  • 8.3 Regenerative Medicine Clinics

9 Global Pet Stem Cell Therapy Market, By Cell Source

  • 9.1 Autologous Adipose Tissue
  • 9.2 Allogeneic Donor Tissue
  • 9.3 Umbilical and Perinatal Tissue
  • 9.4 Other Mesenchymal Cell Sources

10 Global Pet Stem Cell Therapy Market, By Administration Method

  • 10.1 Intra-Articular Injection
  • 10.2 Intravenous Infusion
  • 10.3 Local Tissue Injection
  • 10.4 Other Targeted Administration

11 Global Pet Stem Cell Therapy Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 VetStem, Inc.
  • 14.2 Gallant
  • 14.3 Magellan Stem Cells
  • 14.4 Animal Cell Therapies
  • 14.5 Medrego
  • 14.6 Ardent Animal Health
  • 14.7 VetBiologics
  • 14.8 VetCell Therapeutics
  • 14.9 PetVivo Holdings, Inc.
  • 14.10 Regeneus Ltd.
  • 14.11 Cell Therapy Sciences
  • 14.12 MWI Animal Health
  • 14.13 Cencora, Inc.
  • 14.14 Kintara Therapeutics
  • 14.15 Boehringer Ingelheim Animal Health
  • 14.16 Vetherapy
  • 14.17 Enso Discoveries
Product Code: SMRC41158

List of Tables

  • Table 1 Global Pet Stem Cell Therapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pet Stem Cell Therapy Market Outlook, By Cell Therapy Type (2023-2034) ($MN)
  • Table 3 Global Pet Stem Cell Therapy Market Outlook, By Adipose-Derived Mesenchymal Cells (2023-2034) ($MN)
  • Table 4 Global Pet Stem Cell Therapy Market Outlook, By Umbilical and Placental-Derived Cells (2023-2034) ($MN)
  • Table 5 Global Pet Stem Cell Therapy Market Outlook, By Allogeneic Off-the-Shelf Cells (2023-2034) ($MN)
  • Table 6 Global Pet Stem Cell Therapy Market Outlook, By Autologous Cell Preparations (2023-2034) ($MN)
  • Table 7 Global Pet Stem Cell Therapy Market Outlook, By Clinical Indication (2023-2034) ($MN)
  • Table 8 Global Pet Stem Cell Therapy Market Outlook, By Osteoarthritis (2023-2034) ($MN)
  • Table 9 Global Pet Stem Cell Therapy Market Outlook, By Tendon and Ligament Injuries (2023-2034) ($MN)
  • Table 10 Global Pet Stem Cell Therapy Market Outlook, By Oral and Inflammatory Conditions (2023-2034) ($MN)
  • Table 11 Global Pet Stem Cell Therapy Market Outlook, By Other Degenerative Disorders (2023-2034) ($MN)
  • Table 12 Global Pet Stem Cell Therapy Market Outlook, By Animal Type (2023-2034) ($MN)
  • Table 13 Global Pet Stem Cell Therapy Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 14 Global Pet Stem Cell Therapy Market Outlook, By Cats (2023-2034) ($MN)
  • Table 15 Global Pet Stem Cell Therapy Market Outlook, By Equine Companion Animals (2023-2034) ($MN)
  • Table 16 Global Pet Stem Cell Therapy Market Outlook, By Treatment Setting (2023-2034) ($MN)
  • Table 17 Global Pet Stem Cell Therapy Market Outlook, By Specialty Veterinary Hospitals (2023-2034) ($MN)
  • Table 18 Global Pet Stem Cell Therapy Market Outlook, By Referral Practices (2023-2034) ($MN)
  • Table 19 Global Pet Stem Cell Therapy Market Outlook, By Regenerative Medicine Clinics (2023-2034) ($MN)
  • Table 20 Global Pet Stem Cell Therapy Market Outlook, By Cell Source (2023-2034) ($MN)
  • Table 21 Global Pet Stem Cell Therapy Market Outlook, By Autologous Adipose Tissue (2023-2034) ($MN)
  • Table 22 Global Pet Stem Cell Therapy Market Outlook, By Allogeneic Donor Tissue (2023-2034) ($MN)
  • Table 23 Global Pet Stem Cell Therapy Market Outlook, By Umbilical and Perinatal Tissue (2023-2034) ($MN)
  • Table 24 Global Pet Stem Cell Therapy Market Outlook, By Other Mesenchymal Cell Sources (2023-2034) ($MN)
  • Table 25 Global Pet Stem Cell Therapy Market Outlook, By Administration Method (2023-2034) ($MN)
  • Table 26 Global Pet Stem Cell Therapy Market Outlook, By Intra-Articular Injection (2023-2034) ($MN)
  • Table 27 Global Pet Stem Cell Therapy Market Outlook, By Intravenous Infusion (2023-2034) ($MN)
  • Table 28 Global Pet Stem Cell Therapy Market Outlook, By Local Tissue Injection (2023-2034) ($MN)
  • Table 29 Global Pet Stem Cell Therapy Market Outlook, By Other Targeted Administration (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!